▌Top Stocks · MONTHLY DIVIDEND REITS·Updated June 13, 2026
Top Monthly Dividend REITs Stocks: Our 7 Picks for 2026
These seven monthly dividend REITs span healthcare, industrial, experiential, office, mortgage, and retail, with Realty Income topping the list on overall quality.
Top Stocks · MONTHLY DIVIDEND REITSUpdated June 13, 2026
Monthly dividend REITs stand out in June 2026 because they combine two things income investors still want in a choppy rate backdrop: tangible asset-backed cash flow and a payment schedule that feels closer to a paycheck than a quarterly check. In a higher-rate market, that convenience alone is not enough. Investors have become more selective, favoring REITs that can pair monthly distributions with durable operating cash flow, reasonable balance-sheet discipline, and property portfolios that can hold up through economic stress.
This theme also spans very different business models. Healthcare REITs can benefit from stable demand, but they carry reimbursement and operator risk. Industrial REITs are tied to logistics and e-commerce demand. Experiential landlords can offer stronger growth but face more cyclical tenant exposure. Office REITs remain deeply discounted but structurally challenged. Mortgage REITs often deliver higher yields, yet they are more sensitive to funding costs, spreads, and rate volatility. UDR’s move to monthly common dividends in 2026 reinforces that monthly payout cadence itself has become a meaningful capital-marketing tool.
For investors, the real question is not simply who pays monthly, but which companies have the strongest underlying cash-flow engines to support that cadence over time. That is the lens for this list. The picks below are ranked in countdown order from #7 to #1 based on overall investment quality, balancing business resilience, profitability, growth trends, valuation context, and recent execution.
We screened for U.S.-listed monthly dividend REITs with market capitalizations above $500 million, then ranked them primarily on investment quality rather than headline yield alone. Our review emphasized portfolio durability, profitability, growth, valuation context, analyst sentiment, and recent earnings execution using primary-source financial data and composite metrics. Because this is a countdown, the lower-ranked names appear first and the best overall pick appears last at #1.
What they do. The company owns and invests in healthcare real estate across the United States and Canada, focusing on properties that serve the healthcare industry. As a healthcare REIT, Sabra’s revenue model is tied to rent and property-level cash flow from facilities connected to care delivery, giving it exposure to a demand base that is generally steadier than many cyclical real estate categories.
Why it fits. Healthcare is one of the more defensible corners of the monthly dividend REIT universe, and that makes Sabra relevant even if it ranks near the bottom of this list on quality. The appeal is straightforward: investors looking for monthly income often want property types with recurring demand, and healthcare facilities can offer that, though operator health and reimbursement conditions remain important watchpoints.
Numbers that matter. Sabra generated $815.7 million in revenue with EBITDA of $459.2 million, a 19.15% profit margin, a 31.41% operating margin, and a 63.7% gross margin. Revenue growth was solid at 21.7% year over year, but earnings growth was negative 5.6% and EPS over the trailing 12 months was $0.63, with next-year EPS estimated at $0.7433. Valuation is not especially cheap on earnings, with a trailing P/E of 29.73 and a forward P/E of 32.15. Profitability is respectable but not standout, with ROE of 5.68% and ROA of 3.09%.
Recent momentum. Execution has been uneven. Sabra’s earnings beat rate is just 1 out of 7 reported quarters, and the two most recent completed reports included a 0.0% surprise in April 2026 and a 35.3% miss in February 2026. Analyst sentiment also looks cautious rather than enthusiastic, with 1 Buy and 7 Hold ratings supporting a Neutral consensus and an average target of $22.7692.
What they do. Healthpeak owns, operates, and develops healthcare real estate focused on discovery and delivery. Its portfolio spans outpatient medical, lab, and continuing care retirement community properties, and at September 30, 2025 it held interests in 703 properties, including 530 outpatient medical properties and 139 lab properties. That gives it a broader healthcare platform than many peers.
Why it fits. Monthly dividend REIT investors often want sectors with durable occupancy drivers, and Healthpeak’s concentration in outpatient medical and lab assets fits that profile. The mix is important: lab and outpatient properties can offer more specialized demand characteristics than traditional senior housing alone, which can help support cash-flow resilience even when capital markets are less forgiving.
Numbers that matter. Healthpeak produced $2.87 billion in revenue and $1.54 billion in EBITDA, but profitability remains modest relative to some higher-ranked names, with a 7.73% profit margin, a 12.31% operating margin, and a 58.3% gross margin. Revenue grew 7.1% year over year, while earnings growth surged 363.9%, though that came off a low base and trailing EPS is still only $0.32. Valuation looks demanding on earnings, with a trailing P/E of 64.06 and a forward P/E of 136.99. Returns on capital also remain light, with ROE of 2.8% and ROA of 1.5%.
Recent momentum. Near-term earnings momentum has improved. Healthpeak beat estimates in 3 of the last 7 quarters, including a 460.0% upside surprise in May 2026 and a 66.7% beat in February 2026. Even so, the broader analyst view is mixed, with 5 Buy and 5 Hold ratings, while the composite recommendation sits at Sell and the average target is $21.0556.
What they do.STAG Industrial is focused on acquiring, developing, owning, and operating industrial properties across the United States. As of December 31, 2025, its portfolio included 601 buildings in 41 states totaling about 120.0 million rentable square feet. That scale gives it broad exposure to warehouse and logistics demand rather than a narrow bet on one market.
Why it fits. Industrial REITs are a useful counterweight inside the monthly dividend space because they tap into supply-chain and e-commerce infrastructure rather than healthcare reimbursement or mortgage spread dynamics. For investors who want monthly income backed by physical assets with relatively straightforward rent collection economics, STAG offers one of the cleaner operating models on this list.
Numbers that matter.STAG reported $863.8 million in revenue and $631.7 million in EBITDA, with strong profitability metrics including a 79.7% gross margin, a 37.47% operating margin, and a 28.26% net margin. Revenue growth was 9.1% year over year, but earnings growth was down 34.7%, and next-year EPS is estimated at $1.1377 versus trailing EPS of $1.29. The stock trades at a trailing P/E of 30.06 and a forward P/E of 144.93, so the valuation setup is not especially forgiving. ROE of 6.92% and ROA of 2.92% are decent, though not elite.
Recent momentum. Operational execution has been one of STAG’s strengths. It has beaten estimates in 6 of the last 7 quarters, including a 100.0% beat in February 2026 and a 4.2% beat in April 2026. Analysts remain measured rather than aggressive, with 2 Buy and 7 Hold ratings and an average target of $41.3.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do.EPR is a diversified experiential net lease REIT focused on properties tied to out-of-home leisure and recreation spending. It owns assets across 43 states and Canada and reports approximately $5.5 billion in total assets after accumulated depreciation. Its strategy is differentiated because it underwrites tenant and property cash flow in niches where consumers spend discretionary time and money.
Why it fits.EPR fits this list because monthly dividend investors do not have to stay confined to traditional retail or healthcare real estate. Experiential properties can add a different growth profile, and EPR’s net lease structure can support recurring rent streams. The trade-off is that its tenants are more exposed to discretionary spending cycles than those of many healthcare or industrial peers.
Numbers that matter.EPR generated $720.2 million in revenue and $555.3 million in EBITDA, with standout profitability: a 91.8% gross margin, a 51.31% operating margin, and a 37.73% net margin. ROE of 11.69% and ROA of 4.26% are among the stronger returns in this group. Revenue growth was 3.6% year over year, while earnings growth slipped 5.1%, and next-year EPS is estimated at $3.02 versus trailing EPS of $3.24. Valuation is comparatively reasonable for the list, with a trailing P/E of 18.47 and a forward P/E of 18.52.
Recent momentum.EPR has delivered consistently solid earnings execution, beating estimates in 6 of the last 7 quarters. The most recent completed reports included a 1.5% beat in May 2026 and a 13.6% beat in February 2026. Analyst sentiment is mixed but constructive, with 2 Buy, 8 Hold, and 1 Sell rating, and the consensus average target stands at $61.1.
What they do.AGNC is a mortgage REIT that invests in residential mortgage pass-through securities and collateralized mortgage obligations backed by U.S. government-sponsored enterprises or government agencies. In other words, it is not collecting rent from buildings; it is managing a leveraged portfolio of agency mortgage assets and earning spread income. That makes it structurally different from the equity REITs elsewhere on this list.
Why it fits.AGNC remains one of the benchmark monthly payers in the mortgage REIT category, so it belongs in any serious review of monthly dividend REITs. It offers investors direct exposure to rate-sensitive agency MBS cash flows rather than property-level rents, which can be attractive when spreads are supportive but also more volatile when funding conditions tighten.
Numbers that matter.AGNC reported $1.605 billion in revenue with an exceptionally high 91.71% profit margin and ROE of 13.25%, though mortgage REIT accounting can make margin comparisons with property REITs less straightforward. Revenue growth was 546.1% year over year and earnings growth was 772.4%, with trailing EPS of $1.28 and next-year EPS estimated at $1.5039. Valuation is one of the more appealing on the list, at a trailing P/E of 8.05 and a forward P/E of 6.45. The main quality caveat is leverage sensitivity, reflected in a weak debt-equity component score despite otherwise solid profitability measures.
Recent momentum. Recent earnings have been mixed rather than cleanly positive. AGNC has beaten estimates in 2 of the last 8 quarters, though it did post an 8.4% beat in April 2026 after a 6.1% miss in February 2026. Analysts are broadly in wait-and-see mode, with 3 Buy and 9 Hold ratings and an average target of $11.375.
Pick #2Subscribers only
Subscribers see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This list was built from a universe of U.S.-listed monthly dividend REITs with market capitalizations above $500 million. We ranked the final seven primarily by investment quality, using a blend of business model durability, profitability, growth, valuation context, analyst sentiment, and recent earnings execution. Because monthly dividend lists can change as companies adjust payout policies or market values move, the screen is designed to refresh regularly. The result is a countdown format that starts with the weaker quality setups in the group and ends with the strongest overall pick for this month.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
